UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (62) 62
life sciences & biomedicine (57) 57
humans (52) 52
oncology (47) 47
female (36) 36
male (36) 36
middle aged (34) 34
aged (32) 32
lung neoplasms - drug therapy (30) 30
carcinoma, non-small-cell lung - drug therapy (24) 24
adult (23) 23
cancer (20) 20
lung neoplasms - pathology (18) 18
chemotherapy (14) 14
lung cancer (14) 14
aged, 80 and over (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (13) 13
animals (11) 11
antineoplastic agents - therapeutic use (11) 11
carcinoma, non-small-cell lung - pathology (11) 11
immunotherapy (11) 11
lung cancer, non-small cell (11) 11
lung neoplasms - genetics (11) 11
neoplasm staging (11) 11
treatment outcome (11) 11
care and treatment (10) 10
patients (10) 10
carcinoma, non-small-cell lung - genetics (9) 9
respiratory system (9) 9
mutation (8) 8
pyrazoles - therapeutic use (8) 8
pyridines - therapeutic use (8) 8
research (8) 8
abridged index medicus (7) 7
biomarkers (7) 7
carcinoma, non-small-cell lung - mortality (7) 7
disease-free survival (7) 7
drug therapy (7) 7
hematology, oncology and palliative medicine (7) 7
lung neoplasms - mortality (7) 7
tumors (7) 7
antibodies, monoclonal, humanized - therapeutic use (6) 6
antineoplastic agents - adverse effects (6) 6
antineoplastic combined chemotherapy protocols - adverse effects (6) 6
cancer therapies (6) 6
fatigue (6) 6
metastasis (6) 6
mice (6) 6
neoplasms - drug therapy (6) 6
pembrolizumab (6) 6
prognosis (6) 6
protein kinase inhibitors - therapeutic use (6) 6
apoptosis (5) 5
carbazoles - therapeutic use (5) 5
drug resistance, neoplasm (5) 5
general & internal medicine (5) 5
kaplan-meier estimate (5) 5
lymphocytes (5) 5
medicine, general & internal (5) 5
molecular targeted therapy (5) 5
piperidines - therapeutic use (5) 5
receptor protein-tyrosine kinases - genetics (5) 5
small cell lung carcinoma - drug therapy (5) 5
solid tumors (5) 5
analysis (4) 4
antibodies (4) 4
antibodies, monoclonal - therapeutic use (4) 4
antibodies, monoclonal, humanized - adverse effects (4) 4
brain neoplasms - secondary (4) 4
carcinoma, non-small-cell lung - secondary (4) 4
cohort studies (4) 4
dose-response relationship, drug (4) 4
follow-up studies (4) 4
genetic aspects (4) 4
immunohistochemistry (4) 4
lung cancer, small cell (4) 4
lung neoplasms - immunology (4) 4
lung neoplasms - metabolism (4) 4
lung neoplasms - therapy (4) 4
metal complexes (4) 4
metastases (4) 4
multidisciplinary sciences (4) 4
neoplasms - pathology (4) 4
non-small cell lung cancer (4) 4
non-small cell lung carcinoma (4) 4
pathology (4) 4
pd-l1 protein (4) 4
programmed cell death 1 receptor - antagonists & inhibitors (4) 4
risk factors (4) 4
science & technology - other topics (4) 4
science education (4) 4
small cell lung carcinoma - pathology (4) 4
succinylsulfathiazole (4) 4
sulfisoxazole (4) 4
survival analysis (4) 4
survival rate (4) 4
tumor-infiltrating (4) 4
usage (4) 4
young adult (4) 4
alectinib (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 234 - 242
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Treatment outcome | Care and treatment | Chemotherapy | Usage | Analysis | Lung cancer, Non-small cell | Drug therapy | Cancer | Epidermal growth factor receptors | Laboratories | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Patients | Cancer therapies | Metastases | Pembrolizumab | Hospitals | Platinum | PD-L1 protein | Response rates | Death | Mutation | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2014, Volume 32, Issue 2, pp. 68 - 75
Journal Article
Nature medicine, ISSN 1546-170X, 05/2014, Volume 20, Issue 6, pp. 682 - 688
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 02/2015, Volume 112, Issue 5, pp. 1547 - 1552
Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2015, Volume 372, Issue 21, pp. 2018 - 2028
Journal Article